Edition:
India

Second Sight Medical Products Inc (EYES.OQ)

EYES.OQ on NASDAQ Stock Exchange Capital Market

0.85USD
18 Oct 2019
Change (% chg)

$0.02 (+1.92%)
Prev Close
$0.83
Open
$0.85
Day's High
$0.86
Day's Low
$0.83
Volume
28,559
Avg. Vol
36,991
52-wk High
$1.77
52-wk Low
$0.64

Latest Key Developments (Source: Significant Developments)

Second Sight Medical Products Q2 Loss Per Share $0.07
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.07.Q2 SALES $1.3 MILLION VERSUS $1.9 MILLION.Q2 NON-GAAP LOSS PER SHARE $0.06 EXCLUDING ITEMS.  Full Article

Second Sight Q1 Loss Per Share $0.10
Thursday, 16 May 2019 

May 15 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.10.Q1 SALES $1.1 MILLION VERSUS $1.0 MILLION.Q1 NON-GAAP LOSS PER SHARE $0.07 EXCLUDING ITEMS.EXPECTS TO RECORD A RESTRUCTURING CHARGE OF $0.7 MILLION IN Q2 OF 2019.EXPECTS ITS CASH TO FUND OPERATIONS INTO Q2 OF 2020.AS OF MARCH 31, 2019, SECOND SIGHT HAD $31.7 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Second Sight Reports Fourth Quarter 2018 Business Update
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT REPORTS FOURTH QUARTER 2018 BUSINESS UPDATE.SECOND SIGHT MEDICAL PRODUCTS INC - FULL YEAR 2018 NET REVENUE ESTIMATED TO BE IN RANGE OF $6.5-$6.9 MILLION.SECOND SIGHT MEDICAL PRODUCTS INC - AS OF DECEMBER 31, 2018, SECOND SIGHT HAD $4.5 MILLION IN CASH AND CASH EQUIVALENTS.SECOND SIGHT MEDICAL PRODUCTS - GREGG WILLIAMS, CHAIRMAN OF BOARD OF DIRECTORS, HAS INDICATED HIS INTENTION TO PARTICIPATE IN OFFERING UP TO $20 MILLION.SECOND SIGHT MEDICAL PRODUCTS INC - BELIEVE FUNDS WILL BE SUFFICIENT TO SUPPORT ACTIVITIES THROUGH FIRST HALF OF 2020.  Full Article

Second Sight Medical Products Q3 Loss Per Share $0.12
Thursday, 8 Nov 2018 

Second Sight Medical Products Inc ::SECOND SIGHT REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.Q3 SALES $2.2 MILLION VERSUS $1.6 MILLION.Q3 NON-GAAP LOSS PER SHARE $0.11 EXCLUDING ITEMS.  Full Article

Second Sight Medical Products Says Received $1.6 Mln Grant From Nih For Visual Cortical Prosthesis Trial
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT MEDICAL PRODUCTS - ON SEPT 15, RECEIVED $1.6 MILLION GRANT FROM NIH TO FUND EARLY FEASIBILITY CLINICAL TRIAL OF A VISUAL CORTICAL PROSTHESIS.SECOND SIGHT MEDICAL PRODUCTS - GRANT WITH INTENT TO FUND $6.3 MILLION OVER FIVE YEARS SUBJECT TO ANNUAL REVIEW AND APPROVAL - SEC FILING.  Full Article

Second Sight Appoints John Blake Chief Financial Officer
Thursday, 22 Mar 2018 

March 22 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT APPOINTS JOHN T. BLAKE CHIEF FINANCIAL OFFICER.SECOND SIGHT MEDICAL PRODUCTS INC - BLAKE SUCCEEDS THOMAS MILLER AS CFO.  Full Article

Second Sight Appoints Gregg Williams As Chairman Of The Board Of Directors
Friday, 16 Mar 2018 

March 16 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT APPOINTS GREGG WILLIAMS AS CHAIRMAN OF THE BOARD OF DIRECTORS.SECOND SIGHT APPOINTS GREGG WILLIAMS AS CHAIRMAN OF THE BOARD OF DIRECTORS.SECOND SIGHT MEDICAL PRODUCTS INC - ‍ GREGG WILLIAMS SUCCEEDS ROBERT GREENBERG.SECOND SIGHT MEDICAL PRODUCTS INC - ‍ ROBERT GREENBERG REMAINS A MEMBER OF BOARD​.  Full Article

Second Sight Q4 Loss Per Share $0.13
Thursday, 8 Mar 2018 

March 7 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.13.Q4 SALES $3.1 MILLION VERSUS $715,000.Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.14 EXCLUDING ITEMS.  Full Article

SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION SYSTEM
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Second Sight Medical Products Inc ::SECOND SIGHT RECEIVES FDA EXPEDITED ACCESS PATHWAY DESIGNATION FOR THE ORION CORTICAL VISUAL PROSTHESIS SYSTEM.ORION ALLOWS PATIENTS MORE TIMELY ACCESS TO MEDICAL DEVICES BY EXPEDITING DEVELOPMENT, ASSESSMENT, REVIEW .FDA HAS GRANTED EXPEDITED ACCESS PATHWAY DESIGNATION FOR ORION CORTICAL VISUAL PROSTHESIS SYSTEM​.  Full Article

Second Sight Medical Products reports Q3 loss per share $0.12
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Second Sight Medical Products Inc :Second sight reports third quarter 2017 financial results.Q3 loss per share $0.12.Q3 sales $1.6 million versus $1.2 million.Second Sight Medical Products Inc - qtrly adjusted loss per share $0.11.  Full Article